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Innate immune dysfunction can promote chronic inﬂam-
matory diseases of the liver, such as nonalcoholic fatty
liver disease. Here, we show a role for hepatocyte Toll-
like receptor 5 in detecting ﬂagellin, clearing bacteria
from the liver, and protecting against diet-induced hepatic
diseases.
BACKGROUND & AIMS: Innate immune dysfunction can
promote chronic inﬂammatory diseases of the liver. For
example, mice lacking the ﬂagellin receptor Toll-like
receptor 5 (TLR5) show microbial dysbiosis and predispo-
sition to high-fat diet (HFD)-induced hepatic steatosis.
The extent to which hepatocytes play a direct role in
detecting bacterial products in general, or ﬂagellin in
particular, is poorly understood. In the present study, we
investigated the role of hepatocyte TLR5 in recognizing
ﬂagellin, policing bacteria, and protecting against liver
disease.
METHODS: Mice were engineered to lack TLR5 speciﬁcally in
hepatocytes (TLR5DHep) and analyzed relative to sibling con-
trols (TLR5ﬂ/ﬂ). TLR5 messenger RNA levels, responses to
exogenous ﬂagellin, elimination of circulating motile bacteria,
and susceptibility of liver injury (concanavalin A, carbon
tetrachloride, methionine- and choline-deﬁcient diet, and HFD)
were measured.
RESULTS: TLR5DHep expressed similar levels of TLR5 as
TLR5ﬂ/ﬂ in all organs examined, except in the liver, which
showed a 90% reduction in TLR5 levels, indicating that he-
patocytes accounted for the major portion of TLR5 expression
in this organ. TLR5DHep showed impairment in responding
to puriﬁed ﬂagellin and clearing ﬂagellated bacteria from the
liver. Although TLR5DHep mice did not differ markedly from
sibling controls in concanavalin A or carbon tetrachloride–
induced liver injury models, they showed exacerbated disease
in response to a methionine- and choline-deﬁcient diet
and HFD. Such predisposition of TLR5DHep to diet-induced
liver pathology was associated with increased expression of
proinﬂammatory cytokines, which was dependent on the
Nod-like-receptor C4 inﬂammasome and rescued by micro-
biota ablation.
CONCLUSIONS: Hepatocyte TLR5 plays a critical role in
protecting liver against circulating gut bacteria and against
diet-induced liver disease. (Cell Mol Gastroenterol Hepatol
2016;2:584–604; http://dx.doi.org/10.1016/j.jcmgh.2016.04.007)Keywords: Innate Immunity; TLR5; Hepatocytes; Inﬂammation;
Steatosis.
he mammalian gastrointestinal tract is inhabited byTa complex community of 100 trillion bacteria (1–2
kg in mass), collectively referred to as gut microbiota.
Although gut microbiota play an essential role in host
metabolism and immune system development,1 failure to
manage gut microbiota expeditiously can lead to chronic
inﬂammatory diseases of the intestine such as Crohn’s
disease and ulcerative colitis.2–5 A key means by which the
host manages its microbiota are the Toll-like receptors
(TLRs) and the nod-like receptors (NLRs), which confer the
host innate ability to recognize a broad range of microbes.
Deﬁciency in TLR and/or NLR signaling can result in
changes in microbiota composition that promote intestinal
inﬂammation and metabolic diseases. For example, mice
with engineered deﬁciencies in TLR5, TLR2, NLRP6, or
NLRP3 show altered gut microbiota composition that is
associated with features of the metabolic syndrome, which
could be transferred to WT mice via co-housing and/or fecal
transplant, suggesting a role for microbiota in driving this
disorder.6–8 Such metabolic syndrome included features of
nonalcoholic fatty liver disease (NAFLD) when mice were
fed high-fat diets (HFD).
A primary mechanism by which altered microbiota might
promote NAFLD and other features of metabolic syndrome
is by inducing low-grade inﬂammation, which is a central
feature of these disorders. For example, the altered
microbiota composition of TLR5 knock-out (KO) mice
was associated with higher levels of fecal bioactive
September 2016 Protective Effect of Hepatocyte TLR5 585lipopolysaccharide (LPS) and ﬂagellin, suggesting that
alteration of microbiota may result in inherently greater
potential to promote inﬂammation.9 Although observations
that total loss of TLR function alters microbiota composition
and promotes inﬂammation were suggested to be an artifact
of mouse husbandry practices,10 the observation that
epithelial cell–speciﬁc deletion of TLR5 alters microbiota
composition relative to TLR5-ﬂoxed siblings and results in
low-grade inﬂammation/metabolic syndrome argues
against this notion.11 Such inﬂammation possibly might
result from systemic dissemination of gut microbial prod-
ucts and increasing circulating proinﬂammatory cytokines
in response to these products. Moreover, such microbial
products might themselves disseminate from the intestine,
via portal vein, to the liver and other tissues that do not
normally harbor large populations of bacteria, and are
thought to be very responsive to these products. Such
receiving of intestinal venous blood by the liver has been
proposed to result in the need for the liver to serve as a
ﬁrewall to capture bacteria or their products that breach the
intestine,12 but also might be a means by which aberrant
microbiota promote NAFLD.13 Indeed, the concept that
reduced intestinal barrier function can result in gut micro-
biota products breaching the intestine, sometimes referred
to as leaky gut syndrome, increasingly is thought to play a
central role in metabolic disease.14,15 In support of this
notion, detection of LPS in the liver by Kupffer, macrophage-
like cells, promotes HFD-induced steatosis in mice.16 How-
ever, the extent to which hepatocytes, the predominant cell
type in the liver, play a role in recognizing bacterial prod-
ucts other than LPS remains largely undeﬁned. Because
hepatocytes share many properties with enterocytes, which
are highly responsive to ﬂagellin via TLR5 and normally lack
classic LPS-induced TLR4 signaling,17,18 we reasoned the
former pathway might be operable in hepatocytes.
Hence, we generated mice lacking TLR5 in hepatocytes,
and examined their phenotypes in assays of innate immu-
nity and models of liver injury and inﬂammation. Such
studies showed a role for hepatocyte TLR5 in detecting
bacterial ﬂagellin, clearing bacteria from the liver, and
protecting against diet-induced hepatic disease.Materials and Methods
Generation of Experimental Mice
WT, albumin-CRE, Villin-CRE, and CD11c-CRE mice were
purchased from Jackson Laboratories (Bar Harbor, ME). The
latter were bred to TLR5ﬂ/ﬂmice, whose generation recently
was described11 to create the TLR5ﬂ/ﬂ, TLR5Dhepatocyte (Hep),
TLR5Dintestinal epithelial cell (IEC), and TLR5Ddendritic cell (DC) mice
used herein. The global TLR5KO mice used here originally
were generated by Dr Shizuo Akira (Osaka University,
Osaka, Japan)19 and back-crossed/maintained as previously
described.8 Mice lacking NLRC4 (NLRC4KO), generated on a
pure C57BL/6J background, were kindly provided by Vishva
Dixit (Genentech, Inc, South San Francisco, CA) and used to
generate TLR5/NLRC4 double-KO mice (TLR5-NLRC4 DKO),
as previously described.20 All animals used in this study
were on a C57BL/6J genetic background.All mice were bred and housed at Georgia State
University (Atlanta, GA), under institutionally approved
protocols (Institutional Animal Care and Use Committee
number A14033). Mice were fed with the standard
LabDiet (St. Louis, MO) rodent chow LabDiets 5001 used in
this facility. Where indicated, a HFD (60% of calories from
fat), a methionine and choline-deﬁcient diet (MCD)
(A02082002B). and its associated methionine- and choline-
sufﬁcient control diet (A02082003B) were used to feed the
mice (HFD, 8 weeks; MCD, 4 weeks, as previously
described8,21). All the experiments using HFD and MCD
were performed on female mice, whereas other experi-
ments were performed on either female or male animals. All
the ﬁgures present values obtained from 1 independent
experiment (Figures 1-5 and 7), except for the HFD feeding
experiment (Figures 6 and 8), performed twice.
Flagellin Treatment
Flagellin was isolated and puriﬁed by high-performance
liquid chromatography, as previously described.22 Six-week-
old mice were injected intraperitoneally with 20 mg of pu-
riﬁed ﬂagellin or vehicle (phosphate-buffered saline [PBS])
as a control. Blood was collected at 30 and 120 minutes and
hemolysis-free serum was generated by centrifugation using
serum separator tubes (Becton Dickinson, Franklin Lakes,
NJ). Mice then were euthanized, and organs (liver, lung,
colon, spleen, and kidney) were collected and stored at
-80C for further analysis.
Cytokine Analysis
Serum CXCL1 (chemokine CXC motif ligand 1), inter-
leukin (IL)1b, and IL6 concentrations were determined us-
ing Duoset cytokine enzyme-linked immunosorbent assay
kits (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions. Serum insulin concentration
was determined using the EZRMI-13K rat/mouse insulin
enzyme-linked immunosorbent assay kit (Millipore, Bill-
erica, MA) according to the manufacturer’s instructions.
Quantitative Reverse-Transcription
Polymerase Chain Reaction
Total RNAs were isolated from liver, lung, spleen,
abdominal fat tissue, and colon using TRIzol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
Messenger RNAs (mRNAs) were puriﬁed using the RNeasy
mini kit RNA cleanup procedure (Qiagen, Valenica, CA).
Quantitative reverse-transcription polymerase chain re-
actions (RT-PCRs) were performed using the iScript One-
Step RT-PCR Kit with SYBR Green (Bio-Rad, Hercules, CA)
in a CFX96 apparatus (Bio-Rad) with speciﬁc mouse oligo-
nucleotides (Table 1). Results were normalized to the 36B4
(housekeeping gene).
Intravenous Injection of Bacteria
As previously described,12 live Escherichia coli
(ﬂagellated commensal strain MG1655) was administered
(107 colony forming units [CFU], intravenously) via tail vein.
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free serum was generated by centrifugation using serum
separator tubes (Becton Dickinson). Serum then was diluted
serially, plated on a Luria Bertani agar plate, and incubated
for 12 hours at 37C. CFUs were counted and expressed as
bacteria number per milliliters of blood. In parallel, spleen
and liver were collected, homogenized in sterile PBS, serially
diluted, plated on a Luria Bertani agar plate, and incubated
for 12 hours at 37C. Bacteria then were enumerated and
results are expressed as bacteria per gram of tissue.
Isolation of Hepatic Parenchymal
and Nonparenchymal Cells
Liver perfusion was performed as previously
described.23,24 Brieﬂy, after liver perfusion with perfusion
buffer (Hank’s balanced salt solution, 5 mmol/L HEPES,
0.5 mmol/L EDTA; Sigma, St. Louis, MO) via inferior vena
cava, collagenase solution was perfused (Hank’s balanced
salt solution, 5 mmol/L HEPES, 0.5 mmol/L CaCl2, 0.5 mg/
mL collagenase; Sigma). Digested livers were homogenized
and passed through a 100-mm cell strainer. After centri-
fugation at 50g for 3 minutes, the supernatant was
collected and nonparenchymal cells (NPC) were puriﬁed
using 40% iodixanol solution (Progen, Heidelberg,
Germany). The pelleted parenchymal cells (hepatocytes)
were washed once.
Total RNAs were isolated from puriﬁed hepatocytes and
NPC using TRIzol (Invitrogen) according to the manu-
facturer’s instructions, and quantitative RT-PCRs were
performed as described earlier.
Fluorescence-Activated Cell Sorter–Based
Characterization of Hepatic
Nonparenchymal Cells
Puriﬁed NPC were treated with red blood cell lysis
buffer, and cell preparations were stained with
the following antibody cocktail: CD8a-Paciﬁc Blue (clone
53-6-7; Thermo Fisher Scientiﬁc, Waltham, MA),
CD4-PerCP Cy5.5 (clone RMA 4-5; eBioscience, San Diego,
CA), CD11b–ﬂuorescein isothiocyanate (clone MI-70;
eBioscience), NK1.1-PE-Cy7 (clone PKI 36; eBioscience),
Tie2-PE (clone TEK4; eBioscience), and F4/80-APC (cloneFigure 1. (See previous page). Generation and characterizati
mRNA expression by quantitative RT-PCR in multiple organs
quantitative RT-PCR in the (B) liver, (C) lung, (D) colon, (E) splee
are expressed as relative values compared with the WT group, d
mg of puriﬁed ﬂagellin (þ) or vehicle (200 mL of sterile PBS [-]). Th
Analysis of CXCL1 mRNA expression by quantitative RT-PCR in
TLR5DHep mice. (I) Analysis of CXCL1 protein expression level by
TLR5ﬂ/ﬂ, and TLR5DHep mice. (J and K) Analysis of IL6 mRNA e
mucosa of WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice. (L) Ana
nosorbent assay in the serum of WT, TLR5KO, TLR5ﬂ/ﬂ, and TL
mice were injected intraperitoneally with 20 mg of puriﬁed ﬂage
collected 120 minutes after. (M) Analysis of CXCL1 protein exp
serum of WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice. (N) Anal
nosorbent assay in the serum of WT, TLR5KO, TLR5ﬂ/ﬂ, and TL
representing means ± SEM. (A) Data are the means ± SEM. N
was determined by the Student t test. *P < .05.BM8; eBioscience). Incubation was performed at 4C for
20 minutes, followed by ﬁxation at 37C for 10 minutes in
4% formaldehyde. A total of 20,000 cells were examined
with a BD LRS Fortessa (BD Biosciences, San Jose, CA),
and data were analyzed with FlowJo software version 10
(Ashland, OR). The Live/Dead Yellow staining kit was used
to conﬁrm cell viability (Thermo Fisher Scientiﬁc). Two
gates were designed using forward scatter-A vs side
scatter-A plots (Figure 2C), as previously described.23 G1
was used further to analyze lymphocytes T CD4þ (LT
CD4þ), CD8þ (LT CD8þ), and natural killer (LT NK) using
CD4, CD8a, and NK1.1 markers. G2 was sorted further
using Tie2 and CD11b markers, with CD11bint/high Tie2int/
low subsequently used to analyze Kupffer and myeloid cells
using CD11b and F4/80 markers.
Bacterial Load Quantiﬁcation by
Quantitative RT-PCR
For quantiﬁcation of hepatic bacterial load, total
RNAs were isolated from liver using TRIzol (Invitrogen)
according to the manufacturer’s instructions, and sub-
sequently puriﬁed using the RNeasy Mini Kit (Qiagen).
RNAs then were subjected to quantitative PCR using
the iScript One-Step RT-PCR Kit with SYBR Green with
universal 16S ribosomal RNA primers 515F and 806R
(Table 1). Results were normalized to the housekeeping
36B4 gene.
Assessment of Basal Phenotypes
Mice were weighed after weaning and every week
thereafter. Body weight data shown is expressed as a per-
centage compared with the initial body weight (day 0),
deﬁned as 100%. Eight weeks after weaning (11 weeks old),
mice were fasted for 5 hours, at which time blood was
collected by retro-orbital capillary plexus. Mice then were
euthanized, and colon length, colon weight, spleen weight,
liver, and adipose tissue weights were measured.
Concanavalin A–Induced Hepatitis
Eight-week-old mice were injected intravenously
(tail vein) with Concanavalin A (ConA) (Sigma), 15 mg/kg
of body weight, diluted in sterile pyrogen-free PBS, ason of mice lacking TLR5 in the liver. (A) Analysis of albumin
of WT mice. (B–F) Analysis of TLR5 mRNA expression by
n, and (F) kidney of WT, TLR5ﬂ/ﬂ, and TLR5DHep mice. Results
eﬁned as 1. (G–L) Mice were injected intraperitoneally with 20
irty minutes later, serum and organs were isolated. (G and H)
(G) liver and (H) colonic mucosa of WT, TLR5KO, TLR5ﬂ/ﬂ, and
enzyme-linked immunosorbent assay in sera of WT, TLR5KO,
xpression by quantitative RT-PCR in (J) liver and (K) colonic
lysis of IL6 protein expression level by enzyme-linked immu-
R5DHep mice. (M and N) WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep
llin (þ) or vehicle (200 mL of sterile PBS [-]), and serum were
ression level by enzyme-linked immunosorbent assay in the
ysis of IL6 protein expression level by enzyme-linked immu-
R5DHep mice. (B–N) Points are from individual mice, with bars
¼ 2–6, except for panels I and L, with N ¼ 5–15. Signiﬁcance
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blood was collected by retro-orbital capillary plexus
and hemolysis-free serum was generated by centrifuga-
tion of blood using serum separator tubes (Becton
Dickinson). Mice then were euthanized, and liver weight
was measured and collected for downstream analysis.
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were analyzed at the
Comparative Clinical Pathology Services (Columbia, MO)
under the supervision of a board-certiﬁed veterinary
clinical pathologist (Charles E. Wiedmeyer). A liver
damage score from 1 to 4 was attributed macroscopically
according to abnormal liver surface and to the extent
of lesions. For chronic exposure to ConA, 8-week-old
mice were injected intravenously (tail vein) with ConA
(5 mg/kg of body weight, diluted in sterile pyrogen-free
PBS; Sigma) every week for 3 weeks, for a total of 3
injections. Forty-eight hours after the last injection,
serum and tissues were collected and analyzed, as
described earlier.
Carbon Tetrachloride–Induced Hepatitis
Eight-week-old mice were injected intraperitoneally
with 200 mL of sterile olive oil containing (þ) or not (-)
carbon tetrachloride (CCL4) (1 mL/g of body weight),
as previously described.26 Seventy-two hours after in-
jection, blood was collected by retro-orbital capillary
plexus and hemolysis-free serum was generated by
centrifugation of blood using serum separator tubes
(Becton Dickinson). Serum ALT and AST levels were
analyzed at the Missouri State University metabolic
services core.
Serum ALT and AST Quantiﬁcation
Serum ALT and AST levels were analyzed at the
Comparative Clinical Pathology Services (Columbia, MO)
under the supervision of a board-certiﬁed veterinary clinical
pathologist (Charles E. Wiedmeyer). Results are expressed
as units per liter.
H&E Staining
After euthanasia, mice livers were ﬁxed in 10% buff-
ered formalin for 24 hours at room temperature,Figure 2. (See previous page). Hepatocyte TLR5 helps to m
clearance from liver and spleen. (A and B) Hepatic parenchym
TLR5ﬂ/ﬂ, and TLR5DHep mice. (A) Analysis of albumin mRNA exp
TLR5 mRNA expression by quantitative RT-PCR. Results are exp
WT groups, deﬁned as 1. (C–P) Eight-week-old WT, TLR5K
administered intravenously 107 live ﬂagellated E coli strain M
isolated from noninfected and infected WT, TLR5KO, TLR5ﬂ/ﬂ, a
quantiﬁed by ﬂow cytometry. (C) Representative ﬂow cytometry
T CD8þ (LT CD8þ), (F) lymphocyte T natural killer (LT NK), (G) Ku
percentage of total cells, with 20,000 cells being analyzed. Ana
expression by quantitative RT-PCR in (I, K, and M) puriﬁed hep
as relative values compared with noninfected WT and TLR5ﬂ/ﬂ
in (N) blood, (O) liver homogenate, and (P) spleen homogenate
SEM. No CFUs were detected in mice not administered E coli.
*P < .05.transferred to Ethanol 70, and then embedded in parafﬁn.
Tissues were sectioned at 5-mm thickness and subjected to
H&E staining.
Oil Red Staining
After euthanasia, mice livers were frozen in optimum
cutting temperature and stored at -80C until analysis.
Tissues were sectioned using a cryostat at -20C at 8-mm
thickness and stained with Oil Red O using a previously
described protocol.27 Brieﬂy, 1.9 g of Oil Red O (Sigma)
was dissolved in 300 mL of isopropyl alcohol. After ho-
mogenization, 200 mL of distilled water was added
and the solution was incubated at 4C for 30 minutes.
After ﬁltering (0.45 mm), solution was used to stain OCT
liver sections for 6 minutes. Finally, sections were washed
using running tap water for at least 30 minutes and
mounted using a sterile glycerol 40% solution. Photoshop
CS6 edition (Adobe, San Jose, CA) was used to quantify the
red staining speciﬁcally, using the same settings and
threshold for all of the slides.
Determination of Liver Lipid Contents
After overnight fasting, mice were euthanized and livers
were collected, snap-frozen, and subsequently stored at
-80C. Frozen liver tissues were used for lipid extraction by
the Vanderbilt Mouse Metabolic Phenotyping Center Lipid
Core (DK59637). After extraction, free fatty acid, triglycer-
ide, and cholesterol ester composition were determined.
Determination of Liver Fibrosis
After euthanasia, mouse livers were ﬁxed in 10%
buffered formalin for 24 hours at room temperature,
transferred to Ethanol 70, and then embedded in parafﬁn.
Tissues were sectioned at 5-mm thickness and subjected to
collagen immunostaining (primary antibody: anti-mouse
collagen type I, AB765P; Millipore; secondary antibody:
anti-rabbit IgG cy5) with DNA staining using Hoechst.
Observations were performed with a Zeiss LSM 700
confocal microscope (Zeiss Microscopy, Peabody, MA) with
Zen 2011 software version 7.1. This software was used
to determine the percentage of veins presenting with
collagen accumulation, determined through the examina-
tion of 10 veins per slide. Fibrosis also was evaluated usingaintain basal liver immune state and promotes bacterial
al (hepatocytes) and NPCs were isolated from WT, TLR5KO,
ression in WT animals by quantitative RT-PCR. (B) Analysis of
ressed as relative values compared with (A) hepatocyte or (B)
O, TLR5ﬂ/ﬂ, TLR5DHep, TLR5DIEC, and TLR5DDC mice were
G1655. Hepatic parenchymal (hepatocytes) and NPCs were
nd TLR5DHep mice. Liver NPCs were immunophenotyped and
dot plots. (D) Lymphocyte T CD4þ (LT CD4þ), (E) lymphocyte
pffer cell, and (H) myeloid cell quantiﬁcation, expressed as the
lysis of (I and J) CXCL1, (K and L) IL6, and (M) MCP1 mRNA
atocytes and (J and L) puriﬁed NPC. Results are expressed
groups, deﬁned as 1. (N–P) Six hours after inoculation, CFUs
were enumerated on selective media. Data are the means ±
N ¼ 5–10. Signiﬁcance was determined by the Student t test.
Figure 3. Hepatocyte TLR5 does not play a major role in protecting against acute concanavalin A or CCL4 treatments.
(A–F) WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice were injected intravenously with 200 mL of sterile PBS containing (þ) or not (-)
ConA (15 mg/kg of body weight), and then euthanized 24 hours after injection. (A) Body weight over time. (B) Analysis of
CXCL1 protein expression level by enzyme-linked immunosorbent assay in the serum. (C) Analysis of IL6 protein expression
level by enzyme-linked immunosorbent assay in the serum. (D) Serum ALT concentrations. (E) Serum AST concentrations. (F)
H&E staining of liver sections. (G–J) WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice were injected intraperitoneally with 200 mL of
sterile olive oil containing (þ) or not (-) CCL4 (1 mL/g of body weight), and euthanized 72 hours after injection. (G) Body weight
over time. (H) Analysis of CXCL1 protein expression level by intraperitoneally in the serum. (I) Serum ALT concentrations. (J)
Serum AST concentrations. Scale bar: 50 mm. Data are the means ± SEM. N ¼ 3–5. Signiﬁcance was determined by the
Student t test. *P < .05. CTRL, control.
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and Sirius red (kit ab15068; Abcam) staining, performed
on 5-mm thickness parafﬁn liver sections and following the
manufacturer’s instructions. Photoshop CS6 edition was
used to quantify the red staining speciﬁcally, using the
same settings and threshold for all of the slides.
Determination of Hepatic Hydroxyproline Content
Liver was homogenized in distilled water to a ﬁnal
concentration of 100 mg/mL. A total of 100 mL of 12 mol/L
HCl was added to 100 mL of liver suspension, and samples
were incubated at 120C for 3 hours. Hydrolyzed liver
(50 mL) was added to a 96-well plate and evaporated at
60C. Chloramine T/Oxidation Buffer Mixture (Sigma) was
added and samples were incubated at room temperature
for 5 minutes. Dimethylaminobenzaldehyde reagent was
added, samples were incubated at 60C for 90 minutes, and
absorbance was measured at 560 nm. Puriﬁed hydroxy-
proline was used as a standard.
Overnight Fasting Blood Glucose Measurement
Mice were placed in a clean cage and fasted overnight
for 15 hours. Blood glucose concentration was determined
using a Nova Max Plus Glucose Meter (Billerica, MA) and
expressed as milligrams per deciliters.
Antibiotic Treatment
Four-week-old mice were placed on broad-spectrum
antibiotics ampicillin (1.0 g/L) and neomycin (0.5 g/L) in
drinking water for 14 weeks, as previously described.8
Statistical Analysis
N designate total sample number. Signiﬁcance was
determined using the Student t test or 1-way analysis of
variance using GraphPad Prism software (version
6.04; La Jolla, CA). Differences were noted as signiﬁcant
at a P value of .05 or less. The Kolmogorov–Smirnov test
was used to verify that all data were distributed
normally.
Results
Generation and Characterization of Mice
Lacking Hepatic TLR5
Mice lacking the ﬂagellin receptor, TLR5, are prone to
develop a NAFLD-like phenotype when maintained on a
compositionally deﬁned HFD, possibly as a consequence
of low-grade intestinal inﬂammation and/or a direct lossFigure 4. (See previous page). Hepatocyte TLR5 does not play
treatment.WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice were inje
(5 mg/kg of body weight) every week for 3 weeks, for a total of 3
euthanized. (A) Body weight over time, (B) macroscopic liver d
CXCL1 protein expression level by enzyme-linked immunosorb
level by enzyme-linked immunosorbent assay in the serum. (F) S
Macroscopic picture of livers from ConA-treated WT, TLR5KO,
from ConA-treated WT, TLR5KO, TLR5ﬂ/ﬂ, and TLR5DHep mice
Signiﬁcance was determined by the Student t test. *P < .05.of liver cell TLR5.8 In accord with the latter possibility,
cultured hepatocytes express TLR5 and respond to
ﬂagellin.28 Moreover, we recently observed that loss of gut
epithelial cell TLR5 resulted in low-grade inﬂammation and
some aspects of metabolic syndrome but did not predispose
the liver to HFD-induced nonalcoholic steatohepatitis
(NASH), suggesting a potential role for hepatocyte TLR5 in
protecting the liver in this disease model.11 Hence, we
sought to generate mice that lack TLR5 speciﬁcally in he-
patocytes and, subsequently, investigate their phenotype.
C57BL/6 mice in which exon 1 of the TLR5 gene was
ﬂanked by loxP sites11 were crossed to mice engineered to
express CRE recombinase under the control of the albumin
promoter, allowing subsequent use of a breeding scheme in
which all dams maintained WT TLR5 (TLR5ﬂ/ﬂ) function
while, on average, 50% of each litter would lack TLR5 in
albumin-expressing cells (TLR5DHep). In WT mice, as ex-
pected, albumin mRNA was highly expressed in the liver and
undetectable in other tissues where TLR5 is known to be
expressed, including lung, colon, spleen, and kidney, sug-
gesting our approach would provide highly speciﬁc deletion
of TLR5 in liver (Figure 1A). In accord, TLR5DHep, which
were born at the expected Mendelian ratios and lacked
obvious abnormalities, showed WT levels of TLR5 in all
tissues examined, but had a more than 93% reduction in
TLR5 mRNA in the liver relative to both WT and TLR5ﬂ/ﬂ
mice, showing that depletion of TLR5 was indeed speciﬁc to
the liver and that hepatocytes likely accounted for the major
portion of liver TLR5 expression (Figure 1B–F and Table 2).
To investigate this notion, we isolated and puriﬁed hepa-
tocytes and NPCs, followed by TLR5 mRNA level expression
analysis. As expected, albumin was found to be highly
expressed in the hepatocyte fraction compared with the NPC
fraction (Figure 2A), and this approach showed a strong
97% depletion of TLR5 mRNA in hepatocytes from
TLR5DHep mice compared with TLR5ﬂ/ﬂ animals, with TLR5
mRNA expression being unaffected in NPC (Figure 2B), thus
conﬁrming that the deletion of TLR5 was highly speciﬁc to
hepatocytes.Liver TLR5 Mediates Flagellin-Induced
Gene Expression
We ﬁrst investigated the consequences of hepatocyte-
speciﬁc deletion of TLR5 by measuring responses to
systemic administration of puriﬁed ﬂagellin. Mice were
injected intraperitoneally with ﬂagellin, and various tis-
sues were isolated 30 minutes later, at which time
responses were likely to reﬂect direct responses froma major role in protecting against chronic concanavalin A
cted intravenously with 200 mL of sterile PBS containing ConA
injections. Forty-eight hours after the last injection, mice were
amage, and (C) liver weight were measured. (D) Analysis of
ent assay in the serum. (E) Analysis of IL6 protein expression
erum ALT concentrations. (G) Serum AST concentrations. (H)
TLR5ﬂ/ﬂ, and TLR5DHep mice. (I) H&E staining of liver sections
. Scale bar: 25 mm. Data are the means ± SEM. N ¼ 3–5.
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stimulated by ﬂagellin-induced cytokines. In WT mice,
liver levels of CXCL1 (mouse homologue of IL8) were
highly induced in response to ﬂagellin (Figure 1G–I). In
contrast, no such increase was observed in mice with
complete loss of TLR5, showing the strong TLR5-
dependence of this response. Relative to their TLR5ﬂ/ﬂ
siblings, TLR5DHep showed a 75% reduction in ﬂagellin-
induced CXCL1 levels in the liver, indicating a direct
role for hepatocyte TLR5 in mediating a rapid response to
ﬂagellin, while also suggesting that nonhepatocytes
(eg, Kupffer cells) also might be capable of direct TLR5-
mediated recognition of ﬂagellin. A similar pattern of
results was seen when IL6 was used as the readout for
ﬂagellin responsiveness (Figure 1J–L). In contrast, via
both readouts, rapid responsiveness to ﬂagellin in the
colon was similar in TLR5ﬂ/ﬂ and TLR5DHep, indicating
that the decreased responsiveness observed in the liver
was speciﬁc for that organ (Figure 1G–L). However, the
levels of ﬂagellin-induced CXCL1 and IL6 in serum
were reduced signiﬁcantly, albeit modestly, in TLR5DHep
relative to their TLR5ﬂ/ﬂ siblings at the 30-minute
time point, but not at the 120-minute time point,
which may reﬂect secondary cytokine production
(Figure 1I, and L–N), suggesting that hepatocytes
contribute signiﬁcantly to circulating cytokines in
response to puriﬁed ﬂagellin.Liver TLR5 Promotes Clearance of
Hepatic Bacteria
We next investigated the extent to which loss of he-
patocyte TLR5 might alter populations of nonparenchymal
cells in the liver. First, we performed ﬂow cytometric
analysis of the main hepatic immune cell populations and
observed that, relative to TLR5ﬂ/ﬂ mice, TLR5DHep mice
showed signiﬁcantly decreased levels of CD4þ, CD8þ, and
natural killer lymphocytes, as well as Kupffer cells
(Figure 2C–G). Such reduction correlated with reduced
hepatocyte expression of cytokines CXCL1 and IL6,
which may have inﬂuenced immune cell recruitment
(Figure 2I–M). However, such alterations were not
observed in global TLR5KO mice, suggesting that a broad
range of compensatory factors likely can overcome any
deﬁciency of cell recruitment in even modest inﬂamma-
tory conditions. Hence, we next considered the ability of
TLR5DHep mice to effectively orchestrate innate immunity
upon infection.Figure 5. (See previous page). Liver TLR5 protects against N
WT and TLR5DHep mice were fed with a methionine-and choline
weight over time, (B) spleen weights, (C) liver weights, (D) serum
serum CXCL1 concentrations. (G and H) Liver ﬁbrosis estimatio
(H) quantiﬁcation shown. (I and J) Liver steatosis estimation us
quantiﬁcation shown. (K) Liver ﬁbrosis estimation using Masson
Liver mRNAs were isolated and quantitated for expression of g
factor (TNF)-a, (M) MCP1, and (N) TIMP metallopeptidase inhibi
WT mice fed with control diet group, deﬁned as 1. Scale bar: 5
determined by the Student t test. *P < .05.It recently was shown that the liver protects the host
from the gut microbiota by serving as a “ﬁrewall” that
clears commensal gut bacteria, breaching the gut mucosa
and entering the blood stream via the portal vein.12
Although such liver clearance is presumed to be medi-
ated largely by Kupffer cells, which are macrophage-like
cells, we hypothesized a potential role for hepatocyte
TLR5 in clearing ﬂagellated commensal bacteria. To
investigate this possibility, mice (WT, TLR5KO, TLR5ﬂ/ﬂ,
TLR5DHep, TLR5DIEC, and TLR5DDC) were administered
the commensal, live, ﬂagellated, E coli strain MG1655 by
intravenous injection. Such infection lead to a dramatic
recruitment of myeloid cells, as well as an increase in
proinﬂammatory cytokines (CXCL1, IL6, and monocyte
chimoattractant protein 1 (MCP1)) in both hepatocytes
and NPC, and none of those phenotypes were altered by
TLR5 deletion, either global or liver speciﬁc
(Figure 2H–M). However, relative to their TLR5ﬂ/ﬂ sib-
lings, TLR5DHep showed a 3-fold increase in CFUs in the
liver and spleen, whereas CFUs in blood were not
affected signiﬁcantly (Figure 2N–P). Mice with a complete
deﬁciency of TLR5 showed a similar increase of CFUs in
liver, spleen, and also in the circulating blood, whereas
mice lacking TLR5 expression by intestinal epithelial
cells (TLR5DIEC) or by dendritic cells (TLR5DDC) harbor
CFUs in blood, liver, and spleen not signiﬁcantly
affected compared with TLR5ﬂ/ﬂ control mice. Thus,
although clearance of systemically administered bacteria
likely involves multiple cell types and signaling path-
ways, hepatocyte TLR5 plays a key role in the efﬁcient
orchestration of immune responses that keep bacterial
loads in check in the liver and, subsequently, in the
spleen.Minimal Role for TLR5 in Experimental
Models of Liver Injury
A standard and widely used model for liver injury in
rodents is via administration of ConA, which nonspeciﬁ-
cally activates immune cells, eventuating in liver injury.29
High doses of ConA have been used to model acute liver
injury, and we also designed a new approach by using
lower but multiple doses of ConA to induce chronic rather
than acute liver damage. It has been suggested that the gut
microbiota can function as a rheostat of the immune sys-
tem, and consequently affect the severity of liver disease.
Hence, we subjected TLR5ﬂ/ﬂ and sibling TLR5DHep mice, to
acute (Figure 3A–F) and chronic (Figure 4) ConAASH induced by a methionine- and choline-deﬁcient diet.
-sufﬁcient control diet (Ctrl) or a MCD, for 4 weeks. (A) Body
ALT concentrations, (E) serum AST concentrations, and (F)
n using Sirius red staining, with (G) representative images and
ing Oil Red O staining, with (I) representative images and (J)
’s trichrome staining, with representative images shown. (L–N)
enes involved in inﬂammation and ﬁbrosis: (L) tumor necrosis
tor 1. Results are expressed as relative values compared with
0 mm. Data are the means ± SEM. N ¼ 5. Signiﬁcance was
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consistent with what was described previously for WT
C57BL/6 mice and, more importantly, was not statistically
different between TLR5ﬂ/ﬂ and TLR5DHep mice. CCL4
administration was used as another model of liver injury,
and, again, only a modest and not signiﬁcant increase in
liver injury was observed in TLR5KO and TLR5DHep mice
compared with WT and TLR5ﬂ/ﬂ mice, respectively
(Figure 3G–J). Overall, these data suggest that hepatocyte
TLR5 does not play a major role in classic models of liver
injury.Liver TLR5 Protects Against NASH Induced
by a Methionine- and Choline-Deﬁcient Diet
In light of the increasing appreciation of the role of
innate immunity in mediating NASH, we next examined
the role of hepatocyte TLR5 in a widely used experi-
mental model of this disorder. Speciﬁcally, WT and
TLR5DHep mice were placed on a MCD diet, which is
known to drive steatohepatitis within weeks of its
administration.21,30 As expected, WT mice fed with the
MCD diet showed marked weight loss and developed liver
disease within 4 weeks, as indicated by an increase in
both ALT and AST levels (Figure 5A–F). Importantly,
when fed with the control diet (methionine and choline
sufﬁcient), both ALT and AST levels were increased
signiﬁcantly, albeit modestly, in TLR5DHep compared with
WT mice (Figure 5D and E). When exposed to the MCD
diet, TLR5DHep mice showed a similar degree of wasting,
but showed exacerbated increases in ALT and AST levels
compared with WT animals (Figure 5A, D, and E). This
increase in diet-induced liver injury in TLR5DHep mice
correlated with a decrease in the circulating CXCL1
cytokine level (Figure 5F), suggesting that the enhanced
disease in TLR5DHep mice reﬂected an absence of TLR5-
mediated immune cell recruitment that normally would
prevent and/or remediate liver damage that results from
methionine and choline deﬁciency. We next analyzed
ﬁbrosis and steatosis development, and identiﬁed exac-
erbated collagen ﬁber deposition and liver lipid droplet
accumulation in TLR5DHep compared with WT mice, both
at the basal level (control diet) and after MCD diet
treatment (Figure 5G–K). Inﬂammation-related (tumor
necrosis factor-a and MCP1) and ﬁbrosis-related (TIMP
metallopeptidase inhibitor 1) gene expression were found
be increased in the liver of TLR5DHep compared with WT
mice at the basal level, with further exacerbation after
MCD diet treatment (Figure 5L–N). Altogether, theseFigure 6. (See previous page). Liver TLR5 protects against
(A) Analysis of CXCL1 protein expression level by enzyme-linke
chow diet or a HFD, comprising 60% fat, for 8 weeks. (B–K) TLR
HFD, comprising 60% fat, for 8 weeks. (B) Body weight, (C) fat-p
(E) 5-hour fasting insulinemia, and (F) liver weights were meas
representative images and (H) quantiﬁcation shown. (I) Serum
composition in the liver. FFA, free-fatty acid; TG, triglyceride; C
SEM. (H and I) Points are from individual mice, with bar represen
the Student t test. *P < .05.results show a protective role played by liver TLR5
against NASH.Liver TLR5 Protects Against High-Fat
Diet–Induced Steatosis and Fibrosis
Mice with complete deﬁciency of TLR5 were observed
previously to develop gut bacteria dysbiosis, low-grade
inﬂammation, and features of metabolic syndrome
including increased adiposity and dysglycemia.8 Such
metabolic abnormalities were more pronounced on a HFD
and included hepatic steatosis.8 Most features of TLR5-
deﬁcient metabolic syndrome were recapitulated by
speciﬁc deletion of TLR5 from intestinal epithelial cells
(IEC), suggesting the disorder was driven by the inability
of TLR5-deﬁcient IECs to manage the gut microbiota.11
However, such TLR5DIEC mice did not show increased
steatosis, relative to their sibling control mice, even when
maintained on a HFD, suggesting that this important
feature of their disease might involve loss of TLR5 on
liver cells. Moreover, we observed that HFD feeding leads,
in WT mice, to a substantial increase in circulating CXCL1
levels, suggesting that the TLR5 signaling pathway, and
its associated cytokines, may play a central role in
response to HFD challenge (Figure 6A). Hence, to examine
the possibility that hepatocyte TLR5 might protect
against steatosis, and/or other aspects of metabolic
syndrome, we examined a range of parameters in WT,
TLR5ﬂ/ﬂ, and TLR5DHep mice on a normal chow and HFD.
When maintained on a standard mouse chow diet,
TLR5DHep mice lacked features of low-grade inﬂammation
(no colomegaly or splenomegaly) and metabolic syn-
drome (no modiﬁcation of body mass, fat-pad mass, or
fasting blood glucose) that were shown by mice with a
complete or an IEC TLR5 deﬁciency (Figure 6B–F).8,11
However, relative to their TLR5ﬂ/ﬂ sibling controls,
TLR5DHep showed a signiﬁcant increase, albeit modest, in
liver lipid droplet levels when fed with a regular chow
diet, as shown by levels of Oil Red O staining (Figure 6G
and H). In accord with our previous study, although HFD
treatment leads to moderate steatosis in WT animals,
complete loss of TLR5 resulted in exacerbated levels of
steatosis in response to HFD8 that correlated with
increased levels of liver injury markers, as reﬂected by
levels of serum ALT (Figure 6I). Such increased
susceptibility to HFD-induced liver dysfunction was
recapitulated completely by loss of TLR5 speciﬁcally in
hepatocytes in that, compared with their TLR5ﬂ/ﬂ sib-
lings, TLR5DHep showed marked increased in both levelshigh-fat diet–induced metabolic syndrome and steatosis.
d immunosorbent assay in sera of WT mice fed with a regular
5ﬂ/ﬂ and TLR5DHep mice were fed with a regular chow diet or a
ad weights, (D) 15-hour fasting blood glucose concentration,
ured. (G and H) Liver lipid staining using Oil Red O, with (G)
ALT concentrations. (J) Serum IL1b concentrations. (K) Lipid
E, cholesterol ester. Scale bar: 50 mm. Data are the means ±
ting means ± SEM. N ¼ 5–15. Signiﬁcance was determined by
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(Figure 6G–I). Such liver abnormalities correlated with
increased levels of the proinﬂammatory cytokine IL1b
(Figure 6J), whose increased expression is known to drive
much of the gut pathology shown by mice with complete
deﬁciency of TLR5.31,32 Such increased levels of IL1b in
TLR5-deﬁcient mice were normalized by the global
deletion of the NLRC4 gene, which mediates intracellular
detection of ﬂagellin, resulting in inﬂammasome activa-
tion (Figure 7J). The absence of NLRC4 also prevented
HFD-induced liver and adipose tissue inﬂammation
(Figure 7G–J) compared with TLR5KO animals, suggesting
that increased NLRC4 activation mediated the exacer-
bated liver HFD-induced injury upon loss of hepatocyte
TLR5. The increased lipid accumulation in HFD-treated
TLR5DHep relative to TLR5ﬂ/ﬂ animals was seen in
several lipid species, including free fatty acids, tri-
glycerides, and cholesterol esters (Figure 6K). Such
increased lipid incorporation correlated with increased
expression of the hepatic acetyl-coenzyme A carboxylase
gene, whose activity regulates the availability of sub-
strates for fatty acid synthesis33 in the liver of TLR5DHep
compared with TLR5ﬂ/ﬂ mice (Figure 8A). Analysis of
ﬁbrosis showed increased collagen ﬁber deposition at the
basal level in TLR5KO and TLR5DHep compared with WT
and TLR5ﬂ/ﬂ mice, respectively, as shown by increased
collagen ﬁber deposition, hepatic hydroxyproline (major
component of collagen) concentration, and mild peri-
venular ﬁbrosis (Figure 7A–F). After HFD treatment,
TLR5DHep and TLR5KO mice developed more profound
ﬁbrosis compared with WT and TLR5ﬂ/ﬂ controls
(Figure 7A–F). The absence of NLRC4 was sufﬁcient to
prevent the exacerbated ﬁbrosis observed in TLR5KO
animals, further supporting the role played by NLRC4 in
liver injury observed after the loss of TLR5 (Figure 7A–F).
The development of hepatic steatosis and ﬁbrosis also
was supported by the observation of gene expression
alteration in liver and adipose tissue in response to
HFD treatment, and further exacerbated in TLR5KO and
TLR5DHep animals, including increases in genes that
mediate inﬂammation (CXCL1, IL6, MCP1, tumor necrosis
factor-a, and interferon-g) and ﬁbrosis (TIMP metal-
lopeptidase inhibitor 1, collagen 1, and matrix metal-
loprotease 9) (Figure 8). Importantly, some of those
markers were found to be increased signiﬁcantly in
TLR5DHep animals compared with TLR5ﬂ/ﬂ controls, evenFigure 7. (See previous page). Liver TLR5 protects agains
TLR5DHep, and TLR5-NLRC4 double knock-out (DKO) mice wer
for 8 weeks. (A and B) Liver ﬁbrosis estimation using Sirius r
cation shown. (C) Liver ﬁbrosis estimation using Masson’s tric
droxyproline quantiﬁcation. (E and F) Liver ﬁbrosis estimation
analysis, with (E) representative images (staining of collagen in
vein presenting collagen accumulation, determined through th
adipose tissue mRNA were isolated and quantitated for expre
are expressed as relative values compared with WT mice fed w
expression level by enzyme-linked immunosorbent assay in
enzyme-linked immunosorbent assay in the serum. Scale bar:
determined by the Student t test. *P < .05.under basal conditions (ie, chow-feeding) (Figure 8J),
further supporting a role for liver TLR5 in protecting
against liver disease.
The increased accumulation of lipids, and associated
changes in gene expression, observed in mice lacking
hepatocyte TLR5 also manifested systemically in that
HFD-treated TLR5DHep mice showed modest but signiﬁcant
increases in body weight, fat-pad mass, and fasting
blood glucose/insulinemia, relative to TLR5ﬂ/ﬂ control
mice (Figure 6B–D). Thus, loss of hepatocyte TLR5
predisposed mice to HFD-induced hepatoﬁbrosis and stea-
tosis that promoted other aspects of themetabolic syndrome.Antibiotic Treatment Eliminates High-Fat
Diet–Induced Steatosis That Resulted From
the Loss of Hepatocyte TLR5
Gut epithelial TLR5 protection against gut inﬂammation
is thought to involve this receptor’s role in mediating rapid
recruitment of immune cells that afford expedient clearance
of bacteria that breach the mucosa.11 Extending this logic to
the liver, in conjunction with the general hypothesis that gut
bacteria and/or their products that transit to the liver
promote hepatic disease,14,34,35 suggests that hepatocyte
TLR5 might protect against liver disease by promoting
efﬁcient clearance of bacteria that cross the gut epithelial
barrier and translocate to the liver. In accord with this
hypothesis, we observed that, relative to control TLR5ﬂ/ﬂ
siblings, TLR5DHep mice showed increased levels of bacterial
DNA in the liver when fed with a chow diet (Figure 9A).
Moreover, HFD treatment leads to an increased bacterial
load in the liver of TLR5ﬂ/ﬂ and TLR5DHep mice compared
with chow control groups (Figure 9A), showing that HFD
feeding is associated with a leaky gut syndrome,14,15 which
might explain, at least in part, the uncontrolled liver
inﬂammation in the context of TLR5 deﬁciency. To test this
hypothesis, we maintained TLR5ﬂ/ﬂ and TLR5DHep mice on a
broad-spectrum antibiotic cocktail while being fed chow or
HFD. We observed a signiﬁcant decrease in bacterial DNA
detected in the liver, indicating such antibiotic treatment
ablates the HFD-induced increase in liver bacteria in both
genotypes (Figure 9A). Preventing the increase in liver
bacterial loads is associated with elimination of the differ-
ences in metabolic and liver steatosis phenotype that
was previously observed between TLR5ﬂ/ﬂ and TLR5DHep
mice (Figure 9B–H). Moreover, as previously described,36t high-fat diet–induced ﬁbrosis. WT, TLR5KO, TLR5ﬂ/ﬂ,
e fed with a regular chow diet or a HFD, comprising 60% fat,
ed staining, with (A) representative images and (B) quantiﬁ-
hrome staining, with representative images shown. (D) Hy-
using collagen immunostaining and confocal microscopy
red and DNA in blue), and (F) quantiﬁcation (percentage of
e examination of 10 veins per slide) shown. (G) Liver and (H)
ssion of the CXCL1 gene, involved in inﬂammation. Results
ith regular chow, deﬁned as 1. (I) Analysis of CXCL1 protein
the serum. (J) Analysis of IL1b protein expression level by
50 mm. Data are the means ± SEM. N ¼ 5. Signiﬁcance was
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Table 1.Primers Used in This Study
Gene name Oligonucleotide sequence (5’-3’)
16S 515F GTGCCAGCMGCCGCGGTAA
806R GGACTACHVGGGTWTCTAAT
36B4 TCCAGGCTTTGGGCATCA
CTTTATTCAGCTGCACATCACTCAGA
Albumin GAAGACCCCAGTGAGTGAGC
GCTTCACCAGCTCAGCAAGA
TLR5 ATGGATGCTGAGTTCCCCCA
AAAGGCTATCCTGCCGTCTG
CXCL1 TTGTGCGAAAAGAAGTGCAG
TACAAACACAGCCTCCCACA
IL6 GTGGCTAAGGACCAAGACCA
GGTTTGCCGAGTAGACCTCA
MCP1 GCTGGAGCATCCACGTGTT
TGGGATCATCTTGCTGGTGAA
TNF-a CGAGTGACAAGCCTGTAGCC
CATGCCGTTGGCCAGGA
IFN-g AGCAAGGCGAAAAAGGATGC
TCATTGAATGCTTGGCGCTG
TIMP1 ACAGACAGCCTTCTGCAACT
CGCTGGTATAAGGTGGTCTCG
Collagen-1 CTGGACTTCCTGGTCCTCCT
CCATAGGACATCTGGGAAGCA
MMP9 TAGCTACCTCGAGGGCTTCC
GCCTTGGGTCAGGCTTAGAG
ACC AGCAGATCCGCAGCTTG
ACCTCTGCTCGCTGAGTGC
ACC, acetyl-coenzyme A carboxylase; CXCL1, chemokine
(C-X-C motif) ligand 1; IFN, interferon; IL6, interleukin 6;
MCP1, monocyte chimioattractant; MMP, matrix metal-
loprotease 9; TIMP1, TIMP metallopeptidase inhibitor 1; TLR
5, toll like receptor 5; TNF, tumor necrosis factor.
Table 2.Expression Analysis of TLR5 mRNA in Multiple
Organs in TLR5ﬂ/ﬂ and TLR5DHep Mice
Tissue
Albumin
expression
(relative values)
TLR5 fold decrease
expression in TLR5DHep
mice compared with TLR5ﬂ/ﬂ
mice P
Liver 10,364.08 14.50 <.0001
Lung 0.17 0.88 .2644
Colon 0.01 1.19 .4752
Spleen 0.08 1.09 .5866
Kidney 2.85 1.11 .5991
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development, with an approximately 30% decrease in lipid
accumulation after HFD treatment. Antibiotic treatment also
reduced HFD-induced increases in liver and adipose gene
expression related to inﬂammation (Figure 9I–P). Antibiotic
treatment also abolished the increased ﬁbrosis in TLR5DHep
compared with TLR5ﬂ/ﬂ mice (Figure 9Q–S). Together, these
results indicate that antibiotic treatment abrogated the
increased disease severity in TLR5DHep compared with
TLR5ﬂ/ﬂ animals that otherwise resulted after HFD
feeding (Figure 9B–L). Moreover, antibiotic treatment pre-
vented the severe steatosis observed in TLR5DHep-fed HFDFigure 8. (See previous page). Loss of hepatocyte TLR5 p
expression in liver. WT, TLR5KO, TLR5ﬂ/ﬂ, TLR5DHep, and T
comprising 60% fat, for 8 weeks. (A) Liver mRNAs were isolat
carboxylase gene, involved in lipogenesis. (B and C) Adipose ti
genes involved in inﬂammation: (B) CXCL1 and (C) IL6. (D–I) L
genes involved in inﬂammation and ﬁbrosis: (D) MCP1, (E) tum
(H) collagen 1, and (I) matrix metalloprotease 9. Results are
TLR5ﬂ/ﬂ mice fed with regular chow, deﬁned as 1. Data are the
the Student t test. *P < .05.(Figure 9M–S). Altogether, these results suggest that hepa-
tocyte TLR5 protect against steatosis and inter-related
aspects of the metabolic syndrome through a mechanism
that likely involves efﬁcient clearance of bacteria that
translocate from the gut to the liver.
Discussion
The rapid ascension of NAFLD, and the inter-related
diseases it drives, is a major public health problem that
warrants better understanding of its pathophysiology.
Although increased caloric consumption in general, and
saturated fats in particular, is likely a key driver of fatty
liver disease, the extent of HFD promotion of NAFLD is
driven by a range of genetic and nongenetic determinants.
Gut microbiota increasingly are viewed as acting in con-
cert with a HFD to promote NAFLD. Speciﬁcally, it is hy-
pothesized that gut microbiota-derived LPS translocate,
via the portal vein, to the liver where it activates proin-
ﬂammatory gene expression through TLR4 expressed on
Kupffer cells37 and promotes the onset of disease.16
Accordingly, mice engineered to lack TLR4, globally or in
bone marrow–derived cells, are protected from HFD-
induced steatosis.38 Herein, we describe that, in contrast,
TLR5-mediated detection of bacterial ﬂagellin is mediated
by hepatocytes and protects mice from HFD-induced
NAFLD. Hence, activation of TLRs in the liver is not al-
ways pathologic but, rather, can play an important role in
protecting the liver against chronic inﬂammatory diseases.
Absence of TLR5 on hepatocytes delayed liver clearance
of ﬂagellated bacteria, and such liver-mediated clearance of
bacteria, termed “ﬁrewall function,” is thought to play an
important role in protecting against bacteria that
breach the intestine.12 Hence, considering that HFD can
reduce gut barrier function by reducing tight junctionotentiates high-fat diet–induced proinﬂammatory gene
LR5DIEC mice were fed with a regular chow diet or a HFD,
ed and quantitated for expression of the acetyl-coenzyme A
ssue mRNAs were isolated and quantitated for expression of
iver mRNAs were isolated and quantitated for expression of
or necrosis factor (TNF)-a, (F) interferon (IFN)-g, (G) TIMP1,
expressed as relative values compared with (A–I) WT or (J)
means ± SEM. N ¼ 5–15. Signiﬁcance was determined by
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translocation to the liver, we hypothesize that hepatocyte
TLR5 may protect against HFD-induced steatosis likely by
facilitating rapid clearance of gut-translocating bacteria,
which effectively reduces the extent/duration of proin-
ﬂammatory gene expression in general, and TLR4 activa-
tion in particular, as a result of the reduced bacterial loads.
Such increased loads of ﬂagellated bacteria likely would
result in activation of the ﬂagellin-responsive inﬂamma-
some NLRC4, which plays a pivotal role in driving inﬂam-
mation in mice with a total absence of TLR5,31 leading to
increased IL1b production, which is thought to play an
important role in liver injury and ﬁbrosis.39–41 In support
of this scenario, we observed that the exacerbated steatosis
correlated with enhanced proinﬂammatory gene expres-
sion in general, and increased IL1b cytokine production in
particular, whereas the deletion of NLRC4 prevented HFD-
induced IL1b and, moreover, abrogated NAFLD in TLR5-
deﬁcient mice, although future study will be needed to
determine if NLRC4 activation is occurring in the liver.
Although increased levels of liver bacterial DNA were
observed at basal conditions in TLR5DHep compared with
TLR5ﬂ/ﬂ animals, in accordance with the concept that the
initial impact of an innate immune deﬁciency will be an
increase in bacterial loads, we did not observe any differ-
ence in liver bacterial loads after HFD treatment. This
observation was reminiscent of our results seen in mice
with complete deﬁciency of TLR5 in that, relative to WT
control mice, noncolitic TLR5KO mice harbor a higher load
of adherent gut bacteria, whereas TLR5KO mice with overt
colitis show a lower level of total adherent gut bacteria,42
perhaps reﬂecting that an increased bacterial load pre-
disposes to an inﬂammatory response, which then serves
as a compensatory means to keep bacteria in check. Hence,
we view the increased level of bacteria in the liver of
TLR5DHep mice maintained on normal chow to reﬂect
their discrete innate immune deﬁciency, but that the
liver inﬂammation that ensued upon prolonged high-fat
diet feeding served to limit the bacterial load in this
organ while promoting liver disease. However, at present,
it is also very reasonable to speculate that the ability of
hepatocyte TLR5 to protect against diet-induced liver dis-
ease is independent of its role in promoting bacterial
clearance. Indeed, the ability of TLR5 activation toFigure 9. (See previous page). Antibiotic treatment preven
syndrome, steatosis, and ﬁbrosis that resulted from loss of h
regular chow diet or a HFD, comprising 60% fat, for 8 weeks, wit
administered via drinking water. (A) Analysis of 16S mRNA ex
TLR5DHep mice. (B) Body weight, (C) fat-pad weights, (D) 15-ho
were measured. (F and G) Liver lipid staining using Oil Red O w
Serum ALT concentrations. (I–L) Liver mRNAs were isolated and
and ﬁbrosis: (I) tumor necrosis factor (TNF)-a, (J) TIMP1, (K) c
mRNAs were isolated and quantitated for expression of genes in
and P) Adipose tissue mRNAs were isolated and quantitated for
(P) IL6. Results are expressed as relative values compared with
ﬁbrosis estimation using Sirius red staining with (Q) represent
estimation using Masson’s trichrome staining with representat
SEM. N ¼ 3–5. Signiﬁcance was determined by the Student t tsuppress apoptosis43,44 may underlie its protection against
NAFLD and NASH, resulting from high-fat or MCD diets.
Although the precise mechanism by which activation
of hepatocyte TLR5 promotes bacterial clearance from
the liver has not yet been deﬁned, it may involve
increases in hepatocyte expression of antimicrobial pep-
tides and cytokines, promoting recruitment and activa-
tion of phagocytes that mediate bacterial killing. In
addition, activation of hepatocyte TLR5 in response to
gut-translocating ﬂagellin may induce cytoprotective
gene expression in hepatocytes that allows them to better
withstand the stressful environment that can result from
lipotoxicity and/or proinﬂammatory gene expression.45
These potential mechanisms are analogous to mecha-
nisms by which TLR5 protects the intestine. Speciﬁcally,
TLR5 signaling directly confers epithelia with enhanced
ability to survive a range of challenges46,47 whereas
loss of intestinal epithelial TLR5 results in delayed
clearance of ﬂagellated bacteria, eventuating in chronic
inﬂammation, which can take the form of colitis or low-
grade inﬂammation that is associated with parameters
of the metabolic syndrome.11 Such colitis does not occur
in the absence of TLR4,11 thus, perhaps, the liver and
intestine both follow the paradigm that a discrete deﬁ-
ciency in TLR signaling can result in bacteria expansion
and subsequently enhanced activation of other pathways
of innate immune activation that promote chronic
inﬂammation.
The notion that hepatocytes are the key liver cell type
that responds to ﬂagellin is in accord with recent studies
showing that hepatocytes rapidly and directly respond to
a ﬂagellin analog but not to LPS.28 Accordingly, activation
of liver TLR5 has been proposed to play a central role in
ﬂagellin’s radioprotective and anticancer properties.28
The notion that TLR5 may play a role in chronic liver
disease is supported by the recent clinical study that
found that ﬂagellin-induced IL6 production is impaired in
cirrhosis patients.48 Together with our ﬁndings, these
results support the general theme that activation of innate
immune signaling in nonimmune cells often plays an
important role in homeostasis and, moreover, un-
derscores the concept that broad inhibition of inﬂamma-
tory signaling is unlikely to be a successful means to treat
chronic inﬂammatory diseases of the gut. Rather,ts the exacerbation of high-fat diet–induced metabolic
epatocyte TLR5. TLR5ﬂ/ﬂ and TLR5DHep mice were fed with a
h or without broad-spectrum antibiotics (ampicillin/neomycin),
pression by quantitative RT-PCR in the liver of TLR5ﬂ/ﬂ and
ur fasting blood glucose concentration, and (E) liver weights
ith (F) representative images and (G) quantiﬁcation shown. (H)
quantitated for expression of genes involved in inﬂammation
ollagen 1, and (L) matrix metalloprotease 9. (M and N) Liver
volved in inﬂammation: (M) MCP1 and (N) interferon (IFN)-g. (O
expression of genes involved in inﬂammation: (O) CXCL1 and
TLR5ﬂ/ﬂ mice fed a high-fat diet, deﬁned as 1. (Q and R) Liver
ative images and (R) quantiﬁcation shown. (S) Liver ﬁbrosis
ive images shown. Scale bar: 50 mm. Data are the means ±
est. *P < .05.
September 2016 Protective Effect of Hepatocyte TLR5 603approaches to better manage the gut microbiota so as to
avoid excessive activation of TLR signaling on immune
and nonimmune cells might offer greater long-term
therapeutic potential. Collectively, our results show
that hepatocytes are direct responders to microbial
products and, moreover, play an important role in pro-
tecting the liver against microbiota-driven chronic in-
ﬂammatory diseases.References
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